Adimab is a premier biologics discovery and engineering company specializing in antibodies and multispecifics. Leveraging a proprietary yeast-based platform with fully human synthetic and immunized diversity, Adimab delivers high-quality therapeutic leads with exceptional specificity and developability. Over 15 years, Adimab has partnered with industry leaders to advance more than 600 therapeutic programs. Its expertise spans IgG and HCAb discovery, protein therapeutic engineering, and multispecific generation, including a cutting-edge T cell engager platform, making it a trusted partner in therapeutic innovation.

The convergence of healthcare delivery, life sciences innovation, and academic medicine is ushering in a new era of integrated care and discovery. The result is an ecosystem where healthcare providers, research scientists, medical educators, and insurance partners work seamlessly together, breaking down traditional silos to advance medical knowledge, improve population health, optimize healthcare spending, and train the next generation of clinicians in evidence-based practices powered by cutting-edge technology and informed by real-world data.

Mosaic is your premier partner in drug discovery, offering industry-leading discovery and engineering technologies with integrated in vivo and in vitro workflows. As the exclusive service provider of the Atlas® Full Human Diversity (FHD) Mouse, Mosaic delivers access to an unparalleled in vivo platform for antibody discovery. While our core focus is discovering and validating protein and antibody therapeutics, we also collaborate across nucleic acid-based therapeutics, target validation, and the development of protein and antibody-based tools. We don’t just run assays, we build drug candidates, guided by the strategic insight of seasoned drug hunters, to move programs from ideation to IND-enabling studies and beyond.

Specifica, an IQVIA business, specializes in creating exceptional antibody libraries. Its patented Generation 3 antibody discovery platform delivers developable, high-affinity antibodies directly from selections – minimizing the need for downstream affinity and biophysical engineering. In addition to building and transferring exclusive libraires, Specifica executes discovery campaigns for customers at its lab in Santa Fe, New Mexico.

Telesis Bio is transforming how the world builds biology. Our flagship Gibson SOLA® platform enables on-demand, high-fidelity DNA and mRNA synthesis directly within customer labs—eliminating delays and constraints from traditional outsourcing. By combining enzymatic synthesis chemistry with standard laboratory automation and intuitive design software, Gibson SOLA gives scientists full control over their build timelines, data, and discovery pipelines.

Wheeler Bio is a biomanufacturing pioneer revolutionizing the CDMO model to help innovators bring therapeutic leads to the clinic faster and more efficiently. Based in Oklahoma City, a thriving biohub, Wheeler operates state-of-the-art development labs and a cGMP manufacturing facility. By leveraging strategic partnerships and a modular approach, Wheeler addresses life cycle challenges, ensuring seamless transitions from discovery to Phase 1 clinical trials. Their experienced team delivers tailored solutions, minimizing risks and delays while accelerating therapeutic development.

WuXi Biologics is a leading contract research, development, and manufacturing organization (CRDMO), with the R represented by our premium-quality CRO Services. Backed by drug development expertise, our modular solutions span every stage of biologics research, including antibody discovery, protein production and engineering, and in vitro & in vivo testing. With extensive experience across diverse modalities, such as monoclonal and bispecific antibodies, fusion proteins, TCRs, miniproteins, cytokines, and enzymes, we deliver innovative, customized services to seamlessly advance our clients’ molecules from concept to CMC development.